Average Percent Area Reduction of 97% in 4 weeks in diabetic wounds100% diabetic wound closure in ≤ 12 weeksPreclinical sustained antibiofilm activity for a minimum of 7 days WINNIPEG, Manitoba, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane Biotech” or “Kane”) today announced new clinical and pre-clinical data demonstrating the performance of its FDA-cleared revyve® Antimicrobial Wound Gel and revyve Wound Gel Spray in both diabetic foot ulcer healing and burn wound infection contr ...